| 5 mins | 30 mins | Hourly | Daily | Weekly |
|---|---|---|---|---|
| SELL | SELL | BUY | BUY | BUY |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MA5 | 1.70▼ | 1.71▼ | 1.71▼ | 1.68▲ | 1.60▲ |
| MA10 | 1.71▼ | 1.71▼ | 1.71▼ | 1.69▲ | 1.65▲ |
| MA20 | 1.71▼ | 1.70▼ | 1.71▼ | 1.59▲ | 1.53▲ |
| MA50 | 1.71▼ | 1.69▲ | 1.69▲ | 1.71▼ | 1.65▲ |
| MA100 | 1.71▼ | 1.69▲ | 1.63▲ | 1.47▲ | 1.75▼ |
| MA200 | 1.69▲ | 1.62▲ | 1.58▲ | 1.70▼ | 3.48▼ |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MACD | -0.002▼ | -0.001▼ | -0.001▼ | 0.018▲ | 0.021▲ |
| RSI | 43.690▼ | 48.519▼ | 51.262▲ | 53.643▲ | 52.517▲ |
| STOCH | 4.167▼ | 56.667 | 81.667▲ | 71.654 | 20.000▼ |
| WILL %R | -80.000▼ | -40.000 | -40.000 | -22.222▲ | -72.500 |
| CCI | -108.527▼ | -74.369 | -47.619 | 55.692 | 13.254 |
|
Thursday, May 22, 2025 09:00 AM
Milestone Pharmaceuticals (MIST) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings ...
|
|
Monday, April 07, 2025 11:41 AM
April 07, 2025 — 12:28 pm EDT Written by Quiver ForecastTracker for Quiver Quantitative -> ...
|
|
Thursday, March 13, 2025 12:55 PM
MILESTONE PHARMACEUTICLS Hedge Fund Activity We have seen 23 institutional investors add shares of MILESTONE PHARMACEUTICLS stock to their portfolio, and 19 decrease their positions in their most ...
|
| date | open | high | low | close | volume |
|---|---|---|---|---|---|
| 25/08/25 | 1.70 | 1.73 | 1.66 | 1.69 | 1,532,200 |
| 22/08/25 | 1.70 | 1.72 | 1.68 | 1.70 | 761,100 |
| 21/08/25 | 1.67 | 1.75 | 1.625 | 1.71 | 1,577,200 |
| 20/08/25 | 1.68 | 1.69 | 1.62 | 1.64 | 1,280,753 |
| 19/08/25 | 1.71 | 1.75 | 1.64 | 1.67 | 1,340,000 |
| 18/08/25 | 1.72 | 1.75 | 1.67 | 1.70 | 922,500 |
| 15/08/25 | 1.70 | 1.715 | 1.66 | 1.70 | 866,600 |
| 14/08/25 | 1.74 | 1.74 | 1.605 | 1.68 | 1,455,300 |
| 13/08/25 | 1.71 | 1.74 | 1.64 | 1.74 | 1,376,800 |
| 12/08/25 | 1.55 | 1.66 | 1.54 | 1.66 | 990,868 |
|
|
||||
|
|
||||
|
|